In lung and pancreatic cancers, SMYD3 is localized in the cytoplasm, where it enhances RAS/ERK signaling by mediating the methylation of MAP3K2 kinase and preventing its interaction with the PP2A phosphatase complex [59]. Here, PTPA is linked to pancreatic neoplasm.